Tagged with R

Abbott South Africa Ms Joubert, could you start by telling our readers over the 16 months of heading the operations here, what have been the most challenging situations as the General Manager of Abbott South Africa? I worked in Abbott’s Pharmaceutical Division for 12 years, and then spent 3 years as General Manager…

Abex Pharmaceutica Your professional career went back and forth between creating your own business and running a smaller and very dynamic structure and managing over a thousand of employees for multinational organizations. Could you compare the two and tell us what position you enjoyed the most? I think I prefer the creative…

Dream CIS South Korea has a much shorter history of clinical trials than many other advanced economies. In your view, what is the potential for South Korea’s clinical trial industry today? The quality of Korean medical service is already top notch; it is truly world class. However, the environment here has been…

Teva Czech Republic Mr. Zahradnik, you have long been an active member of the Czech generic drug makers’ association CAFF (Czech Association of Pharmaceutical Firms), chairing the organization. Dr. Zörner, executive director of the CAFF, has remarked that the Czech Republic is a challenging market, but also one in which the authorities have…

Bayer Healthcare South Africa Since we interviewed you in 2005, there have been many changes in the market, from consolidation, an increasing generic penetration, to new healthcare reforms… How have you integrated these changes in the company’s development, and to what extent does Bayer’s recent development reflect the market changes? The first change has…

Aspen The Aspen Group identified Latin America as a “large developing market where it can leverage its substantial intellectual property portfolio and manufacturing infrastructure”. What was the original strategy behind getting the best from the Mexican market – specifically with the acquisition of the Latin America business from India-based Strides Arcolab…

Infinite Clinical Research We understand that Mexico has a lot of advantages for holding clinical trials, including the large population, access to specialized patient populations, higher patient retention rates and cheaper costs by up to 30% when compared to the United States and Europe. In your opinion, what is the most common reason…

Astellas Czech Republic Mr. Chadim, after Astellas was formed from the merger between Yamanouchi and Fujisawa, it became your job to lead its Czech subsidiary. Tapani Sura, your colleague at Astellas Poland, has told Focus Reports that in Poland, Astellas’ first year was a nightmare. “It is safe to say,” he remarked, that…

Stallergenes Czech Republic Mr. Tor, prior to joining Stallergenes in 2010, you had been with MSD for nearly two decades. After such a prolonged experience at a major global pharma player, why did you decide to move down the value chain to a smaller, considerably more specialized biopharmaceutical company like Stallergenes, and what…

Serbian Chamber of Commerce Rather than Mr. Bugarin’s personal views, the following information contains general statements provided by the Serbian Chamber of Commerce Current trends in pharmaceutical industry The production of the medicines in all countries all around the world is one of the most important economic branches, not only as the economic activity,…

Pfizer Serbia Pfizer is increasingly interested in emerging markets, with a focus very much on Latin America and Asia. Given this, why is Serbia exciting for Pfizer today? Serbia is interesting for most multinational companies, firstly because of the county’s geographic location, and secondly because of the relatively high population for the…

Dr. Reddy's Laboratories Romania You have been the first employee to start Dr. Reddy’s in Romania and when we look back at those early years, we see that a portfolio of gastroenterology and analgesics was chosen to enter the market… Why, in the first place, were these therapeutic areas targeted? At that time, the…